# OnCo record nct04842617 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04842617/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04842617", "NCT04842617" ;
  schema:name "Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Ne"@en ;
  schema:description "A phase 3 trial of Dalpiciclib in male breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04842617/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04842617> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-04-30" ;
  onco:cancers <https://onco.cc/cancers/male-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/dalpiciclib/> ;
  onco:companies <https://onco.cc/companies/hengrui/> .